Upcoming

2023

Drug Discovery Informatics Market

Drug Discovery Informatics Market: Global Opportunity Analysis and Industry Forecast 2023-2030 Market

LS : Pharmaceuticals	Report Code: A07074	Nov 2023 \| Pages: NA
Tables: NA	Charts: NA	Formats*: Single User License, Five User License & Enterprise User License Data Pack Excel License It comes with the additional cost of $2500.00 contact sales.

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Drug Discovery Informatics Market

Request Now !

Scientists while performing various researches to discover new treatments for various diseases generate and analyse vast amount of information related to drugs and indications. Discovery informatics utilizes various methods and approaches to in creating such knowledge base and help analyse such huge database to derive valuable insights used in drug discovery process.

Drug-Discovery-Informatics

Drug discovery is a process which requires a huge amount of information. Drug discovery informatics includes databases of various molecules and drugs which are used by various pharmaceutical companies to perform their research. Various software are used to manage and filter the databases. Drug discovery informatics makes use of IT platforms, vital information and other processes to improve and rise over challenges. This sector used modern improvised technology like data storage, processing the data, managing and analysing it.

COVID-19 scenario analysis:

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.

Owing to such factors, COVID 19 is expected to have a significant impact on drug discovery informatics market.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis

The development of the drug discovery informatics is majorly effected by changes in the investment on the research and development, companies working more on the research sector especially on the rare diseases. New inventions in the field of silico tools which have synced computers with workflows to chemistry of drug which has helped stimulate the growth largely. Various pharmaceutical companies are shifting their interest towards drug discovery and the urgent need to limit the drug discovery and its impact on the cost for the drug development are resulting in the growth of the drug discovery informatics market.

Increasing use of technology and shift of approach towards research by pharmaceutical companies are helping boost the demand for drug discovery informatics market. Analysis on the spot by the use of such software is a key factor driving the global drug discovery informatics market.

Having said this, it has been observed that is a lack of professionals who are well aware with this technology along with the cost of investment required to set up informatics software are the major reasons hampering the growth. We have also observed some unacceptable error rates in the databases and unsatisfied end-users as well as providers are the major setbacks for the market.

New product launches to flourish the market:

In 2018, Certara launched a new system of drug informatics system. This was the version 10 of D360.

Jubilant Biosys introduced a major capacity expansions for it drug discover business services in November 2019. Also, Jubilant collaborated with Orion Corporation to work on projects based on the drug discovery informatics market.

In May, 2019, Dassault Systems overtook Medidata Solution and acquired the clinical expertise and cloud-based solutions from them.

In September 2019, Evotec and Takeda Pharmaceutical Company Limited established a five drug discovery program with Evotec’s clinical experts for clinical development for multiple therapy areas.

Selvita has launched a new Development strategy for CROs and how they can plan to grow in the coming years.

Surge in usage in market:

Various pharmaceutical companies have been using this informatics system and softwares for pre clinical research in research and development, compound screening, lead identification and target identification. These companies also use informatics for streamlining the process of drug discovery. Rapid growth in the number of new pharmaceutical as well as biotechnology companies has resulted in the surge in usage of such systems. Well established CROs have also started using the databases resulting in high demand for the softwares.

Key benefits of the report:

This study presents the analytical depiction of the global drug discovery informatics market industry along with the current trends and future estimations to determine the imminent investment pockets.
The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global drug discovery informatics market share.
The current market is quantitatively analyzed to highlight the global market growth scenario.
Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
The report provides a detailed global drug discovery informatics market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Drug discovery informatics market research report:

What are the leading market players active in the drug discovery informatics market?
What the current trends will influence the market in the next few years?
What are the driving factors, restraints, and opportunities in the market?
What are the projections for the future that would help in taking further strategic steps?

Drug Discovery Informatics Market: Global Opportunity Analysis and Industry Forecast 2020-2027 Report Highlights

Aspects	Details
By Application	Drug Discovery Drug Development
By Function	Sequencing and Target Data Analysis Library and Database Preparation Docking Molecular Modelling Others
By Solution	Services Softwares
By End User	Biotechnology Companies Pharmaceutical Companies Contract Research Organizations Other End Users
By Region	North America (U.S., Canada, Mexico) Europe (France, Germany, Italy, Spain, UK, Rest of Europe) Asia-Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific) LAMEA (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players	PerkinElmer Inc, Thermo Fisher Scientific, Cognizant, Infosys Limited, Domainex, Evotec AG, Jubilant Life Sciences Limited, Schrödinger Inc., Selvita, Clarivate Analytics

CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
  - 1.4.1. Primary Research
  - 1.4.2. Secondary Research
  - 1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
  - 3.2.1. Top Investment Pockets
  - 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
  - 3.3.1. Bargaining Power of Suppliers
  - 3.3.2. Threat of New Entrants
  - 3.3.3. Threat of Substitutes
  - 3.3.4. Competitive Rivalry
  - 3.3.5. Bargaining Power among Buyers
- 3.5. Market Dynamics
  - 3.5.1. Drivers
  - 3.5.2. Restraints
  - 3.5.3. Opportunities
- 3.6. COVID-19 Impact Analysis
CHAPTER 4: DRUG DISCOVERY INFORMATICS MARKET, BY APPLICATION
- 4.1. Market Overview
  - 4.1.1 Market Size and Forecast, By Application
- 4.2. Drug Discovery
  - 4.2.1. Key Market Trends, Growth Factors and Opportunities
  - 4.2.2. Market Size and Forecast, By Region
  - 4.2.3. Market Share Analysis, By Country
- 4.3. Drug Development
  - 4.3.1. Key Market Trends, Growth Factors and Opportunities
  - 4.3.2. Market Size and Forecast, By Region
  - 4.3.3. Market Share Analysis, By Country
CHAPTER 5: DRUG DISCOVERY INFORMATICS MARKET, BY FUNCTION
- 5.1. Market Overview
  - 5.1.1 Market Size and Forecast, By Function
- 5.2. Sequencing And Target Data Analysis
  - 5.2.1. Key Market Trends, Growth Factors and Opportunities
  - 5.2.2. Market Size and Forecast, By Region
  - 5.2.3. Market Share Analysis, By Country
- 5.3. Library And Database Preparation
  - 5.3.1. Key Market Trends, Growth Factors and Opportunities
  - 5.3.2. Market Size and Forecast, By Region
  - 5.3.3. Market Share Analysis, By Country
- 5.4. Docking
  - 5.4.1. Key Market Trends, Growth Factors and Opportunities
  - 5.4.2. Market Size and Forecast, By Region
  - 5.4.3. Market Share Analysis, By Country
- 5.5. Molecular Modelling
  - 5.5.1. Key Market Trends, Growth Factors and Opportunities
  - 5.5.2. Market Size and Forecast, By Region
  - 5.5.3. Market Share Analysis, By Country
- 5.6. Others
  - 5.6.1. Key Market Trends, Growth Factors and Opportunities
  - 5.6.2. Market Size and Forecast, By Region
  - 5.6.3. Market Share Analysis, By Country
CHAPTER 6: DRUG DISCOVERY INFORMATICS MARKET, BY SOLUTION
- 6.1. Market Overview
  - 6.1.1 Market Size and Forecast, By Solution
- 6.2. Services
  - 6.2.1. Key Market Trends, Growth Factors and Opportunities
  - 6.2.2. Market Size and Forecast, By Region
  - 6.2.3. Market Share Analysis, By Country
- 6.3. Softwares
  - 6.3.1. Key Market Trends, Growth Factors and Opportunities
  - 6.3.2. Market Size and Forecast, By Region
  - 6.3.3. Market Share Analysis, By Country
CHAPTER 7: DRUG DISCOVERY INFORMATICS MARKET, BY END USER
- 7.1. Market Overview
  - 7.1.1 Market Size and Forecast, By End User
- 7.2. Biotechnology Companies
  - 7.2.1. Key Market Trends, Growth Factors and Opportunities
  - 7.2.2. Market Size and Forecast, By Region
  - 7.2.3. Market Share Analysis, By Country
- 7.3. Pharmaceutical Companies
  - 7.3.1. Key Market Trends, Growth Factors and Opportunities
  - 7.3.2. Market Size and Forecast, By Region
  - 7.3.3. Market Share Analysis, By Country
- 7.4. Contract Research Organizations
  - 7.4.1. Key Market Trends, Growth Factors and Opportunities
  - 7.4.2. Market Size and Forecast, By Region
  - 7.4.3. Market Share Analysis, By Country
- 7.5. Other End Users
  - 7.5.1. Key Market Trends, Growth Factors and Opportunities
  - 7.5.2. Market Size and Forecast, By Region
  - 7.5.3. Market Share Analysis, By Country
CHAPTER 8: DRUG DISCOVERY INFORMATICS MARKET, BY REGION
- 8.1. Market Overview
  - 8.1.1 Market Size and Forecast, By Region
- 8.2. North America
  - 8.2.1. Key Market Trends and Opportunities
  - 8.2.2. Market Size and Forecast, By Application
  - 8.2.3. Market Size and Forecast, By Function
  - 8.2.4. Market Size and Forecast, By Solution
  - 8.2.5. Market Size and Forecast, By End User
  - 8.2.6. Market Size and Forecast, By Country
  - 8.2.7. U.S. Drug Discovery Informatics Market
    - 8.2.7.1. Market Size and Forecast, By Application
    - 8.2.7.2. Market Size and Forecast, By Function
    - 8.2.7.3. Market Size and Forecast, By Solution
    - 8.2.7.4. Market Size and Forecast, By End User
  - 8.2.8. Canada Drug Discovery Informatics Market
    - 8.2.8.1. Market Size and Forecast, By Application
    - 8.2.8.2. Market Size and Forecast, By Function
    - 8.2.8.3. Market Size and Forecast, By Solution
    - 8.2.8.4. Market Size and Forecast, By End User
  - 8.2.9. Mexico Drug Discovery Informatics Market
    - 8.2.9.1. Market Size and Forecast, By Application
    - 8.2.9.2. Market Size and Forecast, By Function
    - 8.2.9.3. Market Size and Forecast, By Solution
    - 8.2.9.4. Market Size and Forecast, By End User
- 8.3. Europe
  - 8.3.1. Key Market Trends and Opportunities
  - 8.3.2. Market Size and Forecast, By Application
  - 8.3.3. Market Size and Forecast, By Function
  - 8.3.4. Market Size and Forecast, By Solution
  - 8.3.5. Market Size and Forecast, By End User
  - 8.3.6. Market Size and Forecast, By Country
  - 8.3.7. France Drug Discovery Informatics Market
    - 8.3.7.1. Market Size and Forecast, By Application
    - 8.3.7.2. Market Size and Forecast, By Function
    - 8.3.7.3. Market Size and Forecast, By Solution
    - 8.3.7.4. Market Size and Forecast, By End User
  - 8.3.8. Germany Drug Discovery Informatics Market
    - 8.3.8.1. Market Size and Forecast, By Application
    - 8.3.8.2. Market Size and Forecast, By Function
    - 8.3.8.3. Market Size and Forecast, By Solution
    - 8.3.8.4. Market Size and Forecast, By End User
  - 8.3.9. Italy Drug Discovery Informatics Market
    - 8.3.9.1. Market Size and Forecast, By Application
    - 8.3.9.2. Market Size and Forecast, By Function
    - 8.3.9.3. Market Size and Forecast, By Solution
    - 8.3.9.4. Market Size and Forecast, By End User
  - 8.3.10. Spain Drug Discovery Informatics Market
    - 8.3.10.1. Market Size and Forecast, By Application
    - 8.3.10.2. Market Size and Forecast, By Function
    - 8.3.10.3. Market Size and Forecast, By Solution
    - 8.3.10.4. Market Size and Forecast, By End User
  - 8.3.11. UK Drug Discovery Informatics Market
    - 8.3.11.1. Market Size and Forecast, By Application
    - 8.3.11.2. Market Size and Forecast, By Function
    - 8.3.11.3. Market Size and Forecast, By Solution
    - 8.3.11.4. Market Size and Forecast, By End User
  - 8.3.12. Russia Drug Discovery Informatics Market
    - 8.3.12.1. Market Size and Forecast, By Application
    - 8.3.12.2. Market Size and Forecast, By Function
    - 8.3.12.3. Market Size and Forecast, By Solution
    - 8.3.12.4. Market Size and Forecast, By End User
  - 8.3.13. Rest Of Europe Drug Discovery Informatics Market
    - 8.3.13.1. Market Size and Forecast, By Application
    - 8.3.13.2. Market Size and Forecast, By Function
    - 8.3.13.3. Market Size and Forecast, By Solution
    - 8.3.13.4. Market Size and Forecast, By End User
- 8.4. Asia-Pacific
  - 8.4.1. Key Market Trends and Opportunities
  - 8.4.2. Market Size and Forecast, By Application
  - 8.4.3. Market Size and Forecast, By Function
  - 8.4.4. Market Size and Forecast, By Solution
  - 8.4.5. Market Size and Forecast, By End User
  - 8.4.6. Market Size and Forecast, By Country
  - 8.4.7. China Drug Discovery Informatics Market
    - 8.4.7.1. Market Size and Forecast, By Application
    - 8.4.7.2. Market Size and Forecast, By Function
    - 8.4.7.3. Market Size and Forecast, By Solution
    - 8.4.7.4. Market Size and Forecast, By End User
  - 8.4.8. Japan Drug Discovery Informatics Market
    - 8.4.8.1. Market Size and Forecast, By Application
    - 8.4.8.2. Market Size and Forecast, By Function
    - 8.4.8.3. Market Size and Forecast, By Solution
    - 8.4.8.4. Market Size and Forecast, By End User
  - 8.4.9. India Drug Discovery Informatics Market
    - 8.4.9.1. Market Size and Forecast, By Application
    - 8.4.9.2. Market Size and Forecast, By Function
    - 8.4.9.3. Market Size and Forecast, By Solution
    - 8.4.9.4. Market Size and Forecast, By End User
  - 8.4.10. South Korea Drug Discovery Informatics Market
    - 8.4.10.1. Market Size and Forecast, By Application
    - 8.4.10.2. Market Size and Forecast, By Function
    - 8.4.10.3. Market Size and Forecast, By Solution
    - 8.4.10.4. Market Size and Forecast, By End User
  - 8.4.11. Australia Drug Discovery Informatics Market
    - 8.4.11.1. Market Size and Forecast, By Application
    - 8.4.11.2. Market Size and Forecast, By Function
    - 8.4.11.3. Market Size and Forecast, By Solution
    - 8.4.11.4. Market Size and Forecast, By End User
  - 8.4.12. Thailand Drug Discovery Informatics Market
    - 8.4.12.1. Market Size and Forecast, By Application
    - 8.4.12.2. Market Size and Forecast, By Function
    - 8.4.12.3. Market Size and Forecast, By Solution
    - 8.4.12.4. Market Size and Forecast, By End User
  - 8.4.13. Malaysia Drug Discovery Informatics Market
    - 8.4.13.1. Market Size and Forecast, By Application
    - 8.4.13.2. Market Size and Forecast, By Function
    - 8.4.13.3. Market Size and Forecast, By Solution
    - 8.4.13.4. Market Size and Forecast, By End User
  - 8.4.14. Indonesia Drug Discovery Informatics Market
    - 8.4.14.1. Market Size and Forecast, By Application
    - 8.4.14.2. Market Size and Forecast, By Function
    - 8.4.14.3. Market Size and Forecast, By Solution
    - 8.4.14.4. Market Size and Forecast, By End User
  - 8.4.15. Rest of Asia Pacific Drug Discovery Informatics Market
    - 8.4.15.1. Market Size and Forecast, By Application
    - 8.4.15.2. Market Size and Forecast, By Function
    - 8.4.15.3. Market Size and Forecast, By Solution
    - 8.4.15.4. Market Size and Forecast, By End User
- 8.5. LAMEA
  - 8.5.1. Key Market Trends and Opportunities
  - 8.5.2. Market Size and Forecast, By Application
  - 8.5.3. Market Size and Forecast, By Function
  - 8.5.4. Market Size and Forecast, By Solution
  - 8.5.5. Market Size and Forecast, By End User
  - 8.5.6. Market Size and Forecast, By Country
  - 8.5.7. Brazil Drug Discovery Informatics Market
    - 8.5.7.1. Market Size and Forecast, By Application
    - 8.5.7.2. Market Size and Forecast, By Function
    - 8.5.7.3. Market Size and Forecast, By Solution
    - 8.5.7.4. Market Size and Forecast, By End User
  - 8.5.8. South Africa Drug Discovery Informatics Market
    - 8.5.8.1. Market Size and Forecast, By Application
    - 8.5.8.2. Market Size and Forecast, By Function
    - 8.5.8.3. Market Size and Forecast, By Solution
    - 8.5.8.4. Market Size and Forecast, By End User
  - 8.5.9. Saudi Arabia Drug Discovery Informatics Market
    - 8.5.9.1. Market Size and Forecast, By Application
    - 8.5.9.2. Market Size and Forecast, By Function
    - 8.5.9.3. Market Size and Forecast, By Solution
    - 8.5.9.4. Market Size and Forecast, By End User
  - 8.5.10. UAE Drug Discovery Informatics Market
    - 8.5.10.1. Market Size and Forecast, By Application
    - 8.5.10.2. Market Size and Forecast, By Function
    - 8.5.10.3. Market Size and Forecast, By Solution
    - 8.5.10.4. Market Size and Forecast, By End User
  - 8.5.11. Argentina Drug Discovery Informatics Market
    - 8.5.11.1. Market Size and Forecast, By Application
    - 8.5.11.2. Market Size and Forecast, By Function
    - 8.5.11.3. Market Size and Forecast, By Solution
    - 8.5.11.4. Market Size and Forecast, By End User
  - 8.5.12. Rest of LAMEA Drug Discovery Informatics Market
    - 8.5.12.1. Market Size and Forecast, By Application
    - 8.5.12.2. Market Size and Forecast, By Function
    - 8.5.12.3. Market Size and Forecast, By Solution
    - 8.5.12.4. Market Size and Forecast, By End User
CHAPTER 9: COMPETITIVE LANDSCAPE
- 9.1. Introduction
- 9.2. Top Winning Strategies
- 9.3. Product Mapping Of Top 10 Player
- 9.4. Competitive Dashboard
- 9.5. Competitive Heatmap
- 9.6. Top Player Positioning,2022
CHAPTER 10: COMPANY PROFILES
- 10.1. PerkinElmer Inc
  - 10.1.1. Company Overview
  - 10.1.2. Key Executives
  - 10.1.3. Company Snapshot
  - 10.1.4. Operating Business Segments
  - 10.1.5. Product Portfolio
  - 10.1.6. Business Performance
  - 10.1.7. Key Strategic Moves and Developments
- 10.2. Schrödinger Inc.
  - 10.2.1. Company Overview
  - 10.2.2. Key Executives
  - 10.2.3. Company Snapshot
  - 10.2.4. Operating Business Segments
  - 10.2.5. Product Portfolio
  - 10.2.6. Business Performance
  - 10.2.7. Key Strategic Moves and Developments
- 10.3. Thermo Fisher Scientific
  - 10.3.1. Company Overview
  - 10.3.2. Key Executives
  - 10.3.3. Company Snapshot
  - 10.3.4. Operating Business Segments
  - 10.3.5. Product Portfolio
  - 10.3.6. Business Performance
  - 10.3.7. Key Strategic Moves and Developments
- 10.4. Clarivate Analytics
  - 10.4.1. Company Overview
  - 10.4.2. Key Executives
  - 10.4.3. Company Snapshot
  - 10.4.4. Operating Business Segments
  - 10.4.5. Product Portfolio
  - 10.4.6. Business Performance
  - 10.4.7. Key Strategic Moves and Developments
- 10.5. Jubilant Life Sciences Limited
  - 10.5.1. Company Overview
  - 10.5.2. Key Executives
  - 10.5.3. Company Snapshot
  - 10.5.4. Operating Business Segments
  - 10.5.5. Product Portfolio
  - 10.5.6. Business Performance
  - 10.5.7. Key Strategic Moves and Developments
- 10.6. Infosys Limited
  - 10.6.1. Company Overview
  - 10.6.2. Key Executives
  - 10.6.3. Company Snapshot
  - 10.6.4. Operating Business Segments
  - 10.6.5. Product Portfolio
  - 10.6.6. Business Performance
  - 10.6.7. Key Strategic Moves and Developments
- 10.7. Selvita
  - 10.7.1. Company Overview
  - 10.7.2. Key Executives
  - 10.7.3. Company Snapshot
  - 10.7.4. Operating Business Segments
  - 10.7.5. Product Portfolio
  - 10.7.6. Business Performance
  - 10.7.7. Key Strategic Moves and Developments
- 10.8. Cognizant
  - 10.8.1. Company Overview
  - 10.8.2. Key Executives
  - 10.8.3. Company Snapshot
  - 10.8.4. Operating Business Segments
  - 10.8.5. Product Portfolio
  - 10.8.6. Business Performance
  - 10.8.7. Key Strategic Moves and Developments
- 10.9. Evotec AG
  - 10.9.1. Company Overview
  - 10.9.2. Key Executives
  - 10.9.3. Company Snapshot
  - 10.9.4. Operating Business Segments
  - 10.9.5. Product Portfolio
  - 10.9.6. Business Performance
  - 10.9.7. Key Strategic Moves and Developments
- 10.10. Domainex
  - 10.10.1. Company Overview
  - 10.10.2. Key Executives
  - 10.10.3. Company Snapshot
  - 10.10.4. Operating Business Segments
  - 10.10.5. Product Portfolio
  - 10.10.6. Business Performance
  - 10.10.7. Key Strategic Moves and Developments

LIST OF TABLES
TABLE 1. GLOBAL DRUG DISCOVERY INFORMATICS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 2. GLOBAL DRUG DISCOVERY INFORMATICS MARKET FOR DRUG DISCOVERY, BY REGION, 2022-2032 ($MILLION)
TABLE 3. GLOBAL DRUG DISCOVERY INFORMATICS MARKET FOR DRUG DEVELOPMENT, BY REGION, 2022-2032 ($MILLION)
TABLE 4. GLOBAL DRUG DISCOVERY INFORMATICS MARKET, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 5. GLOBAL DRUG DISCOVERY INFORMATICS MARKET FOR SEQUENCING AND TARGET DATA ANALYSIS, BY REGION, 2022-2032 ($MILLION)
TABLE 6. GLOBAL DRUG DISCOVERY INFORMATICS MARKET FOR LIBRARY AND DATABASE PREPARATION, BY REGION, 2022-2032 ($MILLION)
TABLE 7. GLOBAL DRUG DISCOVERY INFORMATICS MARKET FOR DOCKING, BY REGION, 2022-2032 ($MILLION)
TABLE 8. GLOBAL DRUG DISCOVERY INFORMATICS MARKET FOR MOLECULAR MODELLING, BY REGION, 2022-2032 ($MILLION)
TABLE 9. GLOBAL DRUG DISCOVERY INFORMATICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 10. GLOBAL DRUG DISCOVERY INFORMATICS MARKET, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 11. GLOBAL DRUG DISCOVERY INFORMATICS MARKET FOR SERVICES, BY REGION, 2022-2032 ($MILLION)
TABLE 12. GLOBAL DRUG DISCOVERY INFORMATICS MARKET FOR SOFTWARES, BY REGION, 2022-2032 ($MILLION)
TABLE 13. GLOBAL DRUG DISCOVERY INFORMATICS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 14. GLOBAL DRUG DISCOVERY INFORMATICS MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2032 ($MILLION)
TABLE 15. GLOBAL DRUG DISCOVERY INFORMATICS MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2022-2032 ($MILLION)
TABLE 16. GLOBAL DRUG DISCOVERY INFORMATICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022-2032 ($MILLION)
TABLE 17. GLOBAL DRUG DISCOVERY INFORMATICS MARKET FOR OTHER END USERS, BY REGION, 2022-2032 ($MILLION)
TABLE 18. GLOBAL DRUG DISCOVERY INFORMATICS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA DRUG DISCOVERY INFORMATICS, BY REGION, 2022-2032 ($MILLION)
TABLE 20. NORTH AMERICA DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 21. NORTH AMERICA DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 22. NORTH AMERICA DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 23. NORTH AMERICA DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 24. U.S. DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 25. U.S. DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 26. U.S. DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 27. U.S. DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 28. CANADA DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 29. CANADA DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 30. CANADA DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 31. CANADA DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 32. MEXICO DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 33. MEXICO DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 34. MEXICO DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 35. MEXICO DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 36. EUROPE DRUG DISCOVERY INFORMATICS, BY REGION, 2022-2032 ($MILLION)
TABLE 37. EUROPE DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 38. EUROPE DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 39. EUROPE DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 40. EUROPE DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 41. FRANCE DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 42. FRANCE DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 43. FRANCE DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 44. FRANCE DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 45. GERMANY DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 46. GERMANY DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 47. GERMANY DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 48. GERMANY DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 49. ITALY DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 50. ITALY DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 51. ITALY DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 52. ITALY DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 53. SPAIN DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 54. SPAIN DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 55. SPAIN DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 56. SPAIN DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 57. UK DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 58. UK DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 59. UK DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 60. UK DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 61. RUSSIA DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 62. RUSSIA DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 63. RUSSIA DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 64. RUSSIA DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 65. REST OF EUROPE DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 66. REST OF EUROPE DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 67. REST OF EUROPE DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 68. REST OF EUROPE DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 69. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS, BY REGION, 2022-2032 ($MILLION)
TABLE 70. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 71. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 72. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 73. ASIA-PACIFIC DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 74. CHINA DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 75. CHINA DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 76. CHINA DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 77. CHINA DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 78. JAPAN DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 79. JAPAN DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 80. JAPAN DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 81. JAPAN DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 82. INDIA DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 83. INDIA DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 84. INDIA DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 85. INDIA DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 86. SOUTH KOREA DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 87. SOUTH KOREA DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 88. SOUTH KOREA DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 89. SOUTH KOREA DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 90. AUSTRALIA DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 91. AUSTRALIA DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 92. AUSTRALIA DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 93. AUSTRALIA DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 94. THAILAND DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 95. THAILAND DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 96. THAILAND DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 97. THAILAND DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 98. MALAYSIA DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 99. MALAYSIA DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 100. MALAYSIA DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 101. MALAYSIA DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 102. INDONESIA DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 103. INDONESIA DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 104. INDONESIA DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 105. INDONESIA DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 106. REST OF ASIA PACIFIC DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 107. REST OF ASIA PACIFIC DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 108. REST OF ASIA PACIFIC DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 109. REST OF ASIA PACIFIC DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 110. LAMEA DRUG DISCOVERY INFORMATICS, BY REGION, 2022-2032 ($MILLION)
TABLE 111. LAMEA DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 112. LAMEA DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 113. LAMEA DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 114. LAMEA DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 115. BRAZIL DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 116. BRAZIL DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 117. BRAZIL DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 118. BRAZIL DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 119. SOUTH AFRICA DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 120. SOUTH AFRICA DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 121. SOUTH AFRICA DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 122. SOUTH AFRICA DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 123. SAUDI ARABIA DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 124. SAUDI ARABIA DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 125. SAUDI ARABIA DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 126. SAUDI ARABIA DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 127. UAE DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 128. UAE DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 129. UAE DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 130. UAE DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 131. ARGENTINA DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 132. ARGENTINA DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 133. ARGENTINA DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 134. ARGENTINA DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 135. REST OF LAMEA DRUG DISCOVERY INFORMATICS, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 136. REST OF LAMEA DRUG DISCOVERY INFORMATICS, BY FUNCTION, 2022-2032 ($MILLION)
TABLE 137. REST OF LAMEA DRUG DISCOVERY INFORMATICS, BY SOLUTION, 2022-2032 ($MILLION)
TABLE 138. REST OF LAMEA DRUG DISCOVERY INFORMATICS, BY END USER, 2022-2032 ($MILLION)
TABLE 139. PERKINELMER INC: KEY EXECUTIVES
TABLE 140. PERKINELMER INC: COMPANY SNAPSHOT
TABLE 141. PERKINELMER INC: OPERATING SEGMENTS
TABLE 142. PERKINELMER INC: PRODUCT PORTFOLIO
TABLE 143. PERKINELMER INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 144. SCHRöDINGER INC.: KEY EXECUTIVES
TABLE 145. SCHRöDINGER INC.: COMPANY SNAPSHOT
TABLE 146. SCHRöDINGER INC.: OPERATING SEGMENTS
TABLE 147. SCHRöDINGER INC.: PRODUCT PORTFOLIO
TABLE 148. SCHRöDINGER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 149. THERMO FISHER SCIENTIFIC: KEY EXECUTIVES
TABLE 150. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
TABLE 151. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
TABLE 152. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 153. THERMO FISHER SCIENTIFIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 154. CLARIVATE ANALYTICS: KEY EXECUTIVES
TABLE 155. CLARIVATE ANALYTICS: COMPANY SNAPSHOT
TABLE 156. CLARIVATE ANALYTICS: OPERATING SEGMENTS
TABLE 157. CLARIVATE ANALYTICS: PRODUCT PORTFOLIO
TABLE 158. CLARIVATE ANALYTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 159. JUBILANT LIFE SCIENCES LIMITED: KEY EXECUTIVES
TABLE 160. JUBILANT LIFE SCIENCES LIMITED: COMPANY SNAPSHOT
TABLE 161. JUBILANT LIFE SCIENCES LIMITED: OPERATING SEGMENTS
TABLE 162. JUBILANT LIFE SCIENCES LIMITED: PRODUCT PORTFOLIO
TABLE 163. JUBILANT LIFE SCIENCES LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 164. INFOSYS LIMITED: KEY EXECUTIVES
TABLE 165. INFOSYS LIMITED: COMPANY SNAPSHOT
TABLE 166. INFOSYS LIMITED: OPERATING SEGMENTS
TABLE 167. INFOSYS LIMITED: PRODUCT PORTFOLIO
TABLE 168. INFOSYS LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 169. SELVITA: KEY EXECUTIVES
TABLE 170. SELVITA: COMPANY SNAPSHOT
TABLE 171. SELVITA: OPERATING SEGMENTS
TABLE 172. SELVITA: PRODUCT PORTFOLIO
TABLE 173. SELVITA: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 174. COGNIZANT: KEY EXECUTIVES
TABLE 175. COGNIZANT: COMPANY SNAPSHOT
TABLE 176. COGNIZANT: OPERATING SEGMENTS
TABLE 177. COGNIZANT: PRODUCT PORTFOLIO
TABLE 178. COGNIZANT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 179. EVOTEC AG: KEY EXECUTIVES
TABLE 180. EVOTEC AG: COMPANY SNAPSHOT
TABLE 181. EVOTEC AG: OPERATING SEGMENTS
TABLE 182. EVOTEC AG: PRODUCT PORTFOLIO
TABLE 183. EVOTEC AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 184. DOMAINEX: KEY EXECUTIVES
TABLE 185. DOMAINEX: COMPANY SNAPSHOT
TABLE 186. DOMAINEX: OPERATING SEGMENTS
TABLE 187. DOMAINEX: PRODUCT PORTFOLIO
TABLE 188. DOMAINEX: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES
FIGURE 1. GLOBAL DRUG DISCOVERY INFORMATICS MARKET SEGMENTATION
FIGURE 2. GLOBAL DRUG DISCOVERY INFORMATICS MARKET
FIGURE 3. SEGMENTATION DRUG DISCOVERY INFORMATICS MARKET
FIGURE 4. TOP INVESTMENT POCKET IN DRUG DISCOVERY INFORMATICS MARKET
FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
FIGURE 8. LOW THREAT OF SUBSTITUTION
FIGURE 9. HIGH COMPETITIVE RIVALRY
FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALDRUG DISCOVERY INFORMATICS MARKET
FIGURE 11. DRUG DISCOVERY INFORMATICS MARKET SEGMENTATION, BY BY APPLICATION
FIGURE 12. DRUG DISCOVERY INFORMATICS MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 13. DRUG DISCOVERY INFORMATICS MARKET FOR DRUG DEVELOPMENT, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 14. DRUG DISCOVERY INFORMATICS MARKET SEGMENTATION, BY BY FUNCTION
FIGURE 15. DRUG DISCOVERY INFORMATICS MARKET FOR SEQUENCING AND TARGET DATA ANALYSIS, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 16. DRUG DISCOVERY INFORMATICS MARKET FOR LIBRARY AND DATABASE PREPARATION, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 17. DRUG DISCOVERY INFORMATICS MARKET FOR DOCKING, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 18. DRUG DISCOVERY INFORMATICS MARKET FOR MOLECULAR MODELLING, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 19. DRUG DISCOVERY INFORMATICS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 20. DRUG DISCOVERY INFORMATICS MARKET SEGMENTATION, BY BY SOLUTION
FIGURE 21. DRUG DISCOVERY INFORMATICS MARKET FOR SERVICES, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 22. DRUG DISCOVERY INFORMATICS MARKET FOR SOFTWARES, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 23. DRUG DISCOVERY INFORMATICS MARKET SEGMENTATION, BY BY END USER
FIGURE 24. DRUG DISCOVERY INFORMATICS MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 25. DRUG DISCOVERY INFORMATICS MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 26. DRUG DISCOVERY INFORMATICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 27. DRUG DISCOVERY INFORMATICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2032 ($MILLION)
FIGURE 28. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
FIGURE 29. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
FIGURE 30. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
FIGURE 31. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 32. COMPETITIVE DASHBOARD
FIGURE 33. COMPETITIVE HEATMAP: DRUG DISCOVERY INFORMATICS MARKET
FIGURE 34. Top player positioning, 2022
FIGURE 35. PERKINELMER INC: NET SALES, 2020-2022 ($MILLION)
FIGURE 36. PERKINELMER INC: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 37. PERKINELMER INC: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 38. SCHRöDINGER INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 39. SCHRöDINGER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 40. SCHRöDINGER INC.: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 41. THERMO FISHER SCIENTIFIC: NET SALES, 2020-2022 ($MILLION)
FIGURE 42. THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 43. THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 44. CLARIVATE ANALYTICS: NET SALES, 2020-2022 ($MILLION)
FIGURE 45. CLARIVATE ANALYTICS: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 46. CLARIVATE ANALYTICS: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 47. JUBILANT LIFE SCIENCES LIMITED: NET SALES, 2020-2022 ($MILLION)
FIGURE 48. JUBILANT LIFE SCIENCES LIMITED: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 49. JUBILANT LIFE SCIENCES LIMITED: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 50. INFOSYS LIMITED: NET SALES, 2020-2022 ($MILLION)
FIGURE 51. INFOSYS LIMITED: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 52. INFOSYS LIMITED: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 53. SELVITA: NET SALES, 2020-2022 ($MILLION)
FIGURE 54. SELVITA: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 55. SELVITA: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 56. COGNIZANT: NET SALES, 2020-2022 ($MILLION)
FIGURE 57. COGNIZANT: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 58. COGNIZANT: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 59. EVOTEC AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 60. EVOTEC AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 61. EVOTEC AG: REVENUE SHARE, BY REGION, 2032 (%)
FIGURE 62. DOMAINEX: NET SALES, 2020-2022 ($MILLION)
FIGURE 63. DOMAINEX: REVENUE SHARE, BY SEGMENT, 2032 (%)
FIGURE 64. DOMAINEX: REVENUE SHARE, BY REGION, 2032 (%)

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

U.S.-Canada Toll-free: +1-800-792-5285
Int'l :	+1-503-894-6022
Europe :	+44-845-528-1300
Email :	help@alliedmarketresearch.com

Life Sciences	Construction & Manufacturing	Semiconductor & Electronics
Consumer Goods	Food & Beverages	Automotive & Tarnsportation
Materials & Chemicals	Energy & Power	ICT & Media
Aerospace & Defense	BFSI
You must check at least one industry.

Your Shopping Cart Is Empty

Continue Shopping

Drug Discovery Informatics Market: Global Opportunity Analysis and Industry Forecast 2020-2027 Global Opportunity Analysis and Industry Forecast 2020-2027

2023

Drug Discovery Informatics Market

Drug Discovery Informatics Market: Global Opportunity Analysis and Industry Forecast 2023-2030 Market

COVID-19

COVID-19 scenario analysis:

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis

New product launches to flourish the market:

Surge in usage in market:

CHAPTER 1: INTRODUCTION

1.1. Report Description

1.2. Key Market Segments

1.3. Key Benefits

1.4. Research Methodology

1.4.1. Primary Research

1.4.2. Secondary Research

1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope

3.2. Key Findings

3.2.1. Top Investment Pockets

3.2.2. Top Winning Strategies

3.3. Porter's Five Forces Analysis

3.3.1. Bargaining Power of Suppliers

3.3.2. Threat of New Entrants

3.3.3. Threat of Substitutes

3.3.4. Competitive Rivalry

3.3.5. Bargaining Power among Buyers

3.5. Market Dynamics

3.5.1. Drivers

3.5.2. Restraints

3.5.3. Opportunities

3.6. COVID-19 Impact Analysis

CHAPTER 4: DRUG DISCOVERY INFORMATICS MARKET, BY APPLICATION

4.1. Market Overview

4.1.1 Market Size and Forecast, By Application

4.2. Drug Discovery

4.2.1. Key Market Trends, Growth Factors and Opportunities

4.2.2. Market Size and Forecast, By Region

4.2.3. Market Share Analysis, By Country

4.3. Drug Development

4.3.1. Key Market Trends, Growth Factors and Opportunities

4.3.2. Market Size and Forecast, By Region

4.3.3. Market Share Analysis, By Country

CHAPTER 5: DRUG DISCOVERY INFORMATICS MARKET, BY FUNCTION

5.1. Market Overview

5.1.1 Market Size and Forecast, By Function

5.2. Sequencing And Target Data Analysis

5.2.1. Key Market Trends, Growth Factors and Opportunities

5.2.2. Market Size and Forecast, By Region

5.2.3. Market Share Analysis, By Country

5.3. Library And Database Preparation

5.3.1. Key Market Trends, Growth Factors and Opportunities

5.3.2. Market Size and Forecast, By Region

5.3.3. Market Share Analysis, By Country

5.4. Docking

5.4.1. Key Market Trends, Growth Factors and Opportunities

5.4.2. Market Size and Forecast, By Region

5.4.3. Market Share Analysis, By Country

5.5. Molecular Modelling

5.5.1. Key Market Trends, Growth Factors and Opportunities

5.5.2. Market Size and Forecast, By Region

5.5.3. Market Share Analysis, By Country

5.6. Others

5.6.1. Key Market Trends, Growth Factors and Opportunities

5.6.2. Market Size and Forecast, By Region

5.6.3. Market Share Analysis, By Country

CHAPTER 6: DRUG DISCOVERY INFORMATICS MARKET, BY SOLUTION

6.1. Market Overview

6.1.1 Market Size and Forecast, By Solution

6.2. Services

6.2.1. Key Market Trends, Growth Factors and Opportunities

6.2.2. Market Size and Forecast, By Region

6.2.3. Market Share Analysis, By Country

6.3. Softwares

6.3.1. Key Market Trends, Growth Factors and Opportunities

Drug Discovery Informatics Market: Global Opportunity Analysis and Industry Forecast 2020-2027
Global Opportunity Analysis and Industry Forecast 2020-2027